IO Biotech
IOBT
IOBT was delisted on the 6th of April, 2026.
26 hedge funds and large institutions have $25.3M invested in IO Biotech in 2025 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
21% more capital invested
Capital invested by funds: $20.8M → $25.3M (+$4.44M)
18% more funds holding
Funds holding: 22 → 26 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.41% less ownership
Funds ownership: 29.01% → 27.6% (-1.4%)
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
+$27.7K |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$26K |
| 3 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$15K |
| 4 |
Renaissance Technologies
New York
|
+$14.8K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$11.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$423K |
| 2 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
-$409K |
| 3 |
Morgan Stanley
New York
|
-$155K |
| 4 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
-$60.5K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$41.7K |
IOBT Hedge Fund Activity: Q2 2025 in Review
26 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in IO Biotech (IOBT) for Q2 2025, worth a combined $25.3M — up 21% from $20.8M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new IOBT positions and 1 closed out — a net gain of 4 holders — while 5 added to existing stakes and 8 trimmed.
The largest buyer was NewEdge Advisors, opening a new position worth an estimated $27.7K. The largest seller was PFM Health Sciences, cutting an estimated $423K.
- 26 institutional investors held IO Biotech (IOBT) as of Q2 2025, up from 22 in Q1 2025.
- Funds reported $25.3M of IO Biotech stock for Q2 2025, up 21% quarter-over-quarter.
- 5 funds opened new IO Biotech positions in Q2 2025 and 1 closed out, a net change of +4 holders.
- The largest IO Biotech buyer in Q2 2025 was NewEdge Advisors, an estimated $27.7K added.
- The largest IO Biotech seller in Q2 2025 was PFM Health Sciences, an estimated $423K sold.
Based on aggregated 13F filings for Q2 2025.